Showing results (111-120 of 156) with videos related to

Sort By:
Pageof 16
Annals of Hepatology|August 16, 2025
Primary biliary cholangitis has the worst quality of life indicators among the autoimmune liver diseases: A United States cohortLeandro Sierra, Bryan Ferrigno, Ana Marenco-Flores, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 21, 2017
Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral TherapyIra M Jacobson, Mary K Washington, Maria Buti, et al.
Journal of Clinical and Translational Hepatology|October 28, 2022
Regional and National Trends of Adult Living Donor Liver Transplantation in the United States Over the Last Two DecadesSaleh A Alqahtani, Ahmet Gurakar, Hani Tamim, et al.
Annals of Hepatology|May 31, 2026
Longitudinal health-related quality of life and associated factors in autoimmune liver diseasesDami Ko, Vilas Patwardhan, Natalia Rojas-Amaris, et al.
Hepatology Communications|April 14, 2025
A nationwide study of primary biliary cholangitis prevalence, geographic distribution, and health care providersCynthia Levy, Keri-Ann Buchanan-Peart, Joanna P MacEwan, et al.
Hepatology (Baltimore, Md.)|September 27, 2007
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trialIra M Jacobson, Robert S Brown, Bradley Freilich, et al.
Hepatology (Baltimore, Md.)|February 15, 2019
Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2)Markus Peck-Radosavljevic, Krzysztof Simon, Angelo Iacobellis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 30, 2019
Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018Tengiz Tsertsvadze, Amiran Gamkrelidze, Nikoloz Chkhartishvili, et al.
Open Forum Infectious Diseases|February 17, 2018
Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 StudiesJason Grebely, Jordan J Feld, David Wyles, et al.
Hepatology (Baltimore, Md.)|November 9, 2015
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 dataJulius M Wilder, Lennox J Jeffers, Natarajan Ravendhran, et al.
Pageof 16